Diagnostic Test Accuracy Protocol
Calcitonin testing for detection of medullary thyroid cancer in patients with thyroid nodules
Editorial Group: Cochrane Metabolic and Endocrine Disorders Group
Published Online: 17 OCT 2012
Assessed as up-to-date: 20 AUG 2012
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Verbeek HHG, de Groot JWB, Sluiter WJ, Muller Kobold AC, Plukker JTM, Links TP. Calcitonin testing for detection of medullary thyroid cancer in patients with thyroid nodules (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010159. DOI: 10.1002/14651858.CD010159.
- Publication Status: New
- Published Online: 17 OCT 2012
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this review is to determine the diagnostic accuracy of calcitonin testing in the detection of MTC in patients with thyroid nodules.
We will investigate whether calcitonin screening should be performed in all patients with thyroid nodules or whether screening should be limited to subgroups of patients. Firstly we will test differences in cut-off values, assay types and different verification methods as these are likely to have the most influence on heterogeneity. Depending on the number of included studies, we will perform further subgroup analyses.
- Nodules detected by palpation or ultrasound.
- Nodule size.
- Number of nodules.
- Sonographic morphology of thyroid nodules.
- FNA procedures performed through ultrasound guidance versus palpation.
- Basal versus stimulated calcitonin testing.